CD274 and renal cell carcinoma: The cancer therapy, especially for RCC, has been revolutionized based on the use of immune checkpoint inhibitors with targets such as programmed death 1 (PD-1), PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).